Plain-English translation of NCT01731665 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →This is a research study that looks at how inflammatory bowel disease—a chronic condition affecting the digestive tract—has changed over 30 years in Seoul, Korea. Researchers will review medical records and information from people diagnosed with Crohn's disease or ulcerative colitis to understand how common these diseases are, what symptoms patients experience, and how the disease progresses over time.
Inflammatory bowel disease is becoming more common in Korea, but doctors still don't fully understand how the disease behaves in Korean patients or what the long-term outlook is. By studying patients over three decades, researchers hope to identify patterns that will help improve diagnosis and treatment for future patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, researchers will review your medical records, test results, and hospital visits to gather information about your disease—from when you were first diagnosed through 2017. You won't need to take any new medication or come in for extra appointments. The study is simply collecting and analyzing existing medical information to understand patterns in how inflammatory bowel disease develops and progresses in Seoul.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea
Sponsor
Asan Medical Center
Collaborators
Kyung Hee University Hospital at Gangdong, Seoul National University Hospital
Enrollment target
~2,000 participants
Started
December 2012
Primary completion
June 2029
Last updated on clinicaltrials.gov in January 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Suk-Kyun Yang, M.D.
Asan Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.